NCT07450664Enrolling by invitation
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
An Observational Study of VYKAT™ XR (Diazoxide Choline Extended-Release Tablets) in Patients With Prader-Willi Syndrome (PWS)
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
Prospective observational study developed to generate more evidence of the safety profile, clinical characteristics and outcomes of patients with PWS treated with VYKAT XR.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 9 Feb 2026
- Start date
- 26 Nov 2025
- Primary completion date
- Mar 2028
- Lead sponsor
- Soleno Therapeutics, Inc.
- NCT number
- NCT07450664
What you commit to
- Study type: Observational
- Planned participants: 200
- From 26 Nov 2025 to the primary completion date, Mar 2028
- 25 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patients currently receiving or initiating treatment with VYKAT XR, including patients who previously received DCCR or are transitioning from DCCR to VYKAT XR in the context of a prior DCCR clinical trial.
- Patients and/or caregivers must provide written informed consent.
Age in the registry: 4 years to - · Sex: All · Does not accept healthy volunteers
Sites (25)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.